Phase II Trial of in Situ Tumor Vaccination Using Durvalumab and "Booster" Radiation Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Through First-line Chemotherapy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 17 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 20 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.
- 21 Feb 2017 Planned initiation date changed from 1 Mar 2017 to 1 May 2017.